Cidara’s Rezafungin Hits Approvable Endpoints For Candida Infections

 
• By Joseph Haas
IV solution in a child's patients hand
Cidara hopes its weekly I.V. antifungal will improve therapy for Candida infections

More from Clinical Trials

More from R&D